Cipla announces closure of USFDA inspection at Patalganga facility

Cipla recently announced the closure of inspection by United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility in Maharashtra. Shares of Cipla were trading 0.40 per cent lower at Rs 478.35 apiece on the BSE in the morning trade.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news